Vaccine-relevant human papillomavirus (HPV) infections and future acquisition of high-risk HPV types in men.
BACKGROUND
Little is known about type-specific associations between prevalent human papillomavirus (HPV) infections and risk of acquiring other HPV types in men. Data on natural clustering of HPV types are needed as a prevaccine distribution to which postvaccine data can be compared.


METHODS
Using data from a randomized controlled trial of male circumcision in Kisumu, Kenya, adjusted mean survival ratios were estimated for acquisition of any-HPV, high-risk (HR) HPV, and individual HR-HPV types among men uninfected as compared to those infected with vaccine-relevant HPV types 16, 18, 31, 45, 6, or 11 at baseline.


RESULTS
Among 1097 human immunodeficiency virus-negative, uncircumcised men, 2303 incident HPV infections were detected over 2534 person-years of follow-up. Although acquisition of individual HR-HPV types varied by baseline HPV type, there was no clear evidence of shorter times to acquisition among men without vaccine-relevant HPV-16, -18, -31, -45, -6, or -11 infections at baseline, as compared to men who did have these infections at baseline.


CONCLUSIONS
These prospective data on combinations of HPV infections over time do not suggest the potential for postvaccination HPV type replacement. Future surveillance studies are needed to definitely determine whether elimination of HPV types by vaccination will alter the HPV type distribution in the population.
Department of Epidemiology, University of North Carolina, Chapel Hill, USA. arositch@jhsph.edu
Anne F
AF
Rositch
Michael G
MG
Hudgens
Danielle M
DM
Backes
Stephen
S
Moses
Kawango
K
Agot
Edith
E
Nyagaya
Peter J F
PJ
Snijders
Chris J L M
CJ
Meijer
Robert C
RC
Bailey
Jennifer S
JS
Smith
D000293:Adolescent; D015331:Cohort Studies; D004279:DNA, Viral / Q000737:chemistry / Q000235:genetics; D005838:Genotype; D006801:Humans; D015994:Incidence; D053208:Kaplan-Meier Estimate; D007630:Kenya / Q000453:epidemiology; D008297:Male; D027383:Papillomaviridae / Q000276:immunology* / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control / Q000821:virology*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D016133:Polymerase Chain Reaction; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D011795:Surveys and Questionnaires; D055815:Young Adult
D004279:DNA, Viral; D053918:Papillomavirus Vaccines